Concepedia

Publication | Open Access

Dolutegravir in antiretroviral-naive adults with HIV-1

DOIFull Paper Access

158

Citations

14

References

2013

Year

Hans-Jürgen Stellbrink, Jacques Reynes, Adriano Lazzarin, Eugene Voronin, Federico Pulido, Franco Felizarta, Steve Almond, Marty St. Clair, Nancy Flack, Sherene Min
AIDS

Abstract

Throughout the 96 weeks of the SPRING-1 study, DTG demonstrated sustained efficacy and favorable safety/tolerability in treatment-naive individuals with HIV-1.

References

YearCitations

Page 1